scholarly journals Effects of Metformin compared to Thiazolidinediones on vascular endothelial function in Polycystic Ovary syndrome: A systematic review

2020 ◽  
Author(s):  
Hoimonty Mazumder ◽  
Farah Faizah ◽  
Md. Mahbub Hossain
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Endothelial Function ◽  
Polycystic Ovary ◽  
P Value ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Vascular Endothelial ◽  
Vascular Endothelial Function ◽  
Ovary Syndrome ◽  
Significant Difference

AbstractMetformin and Thiazolidinediones are insulin sensitizers used as the first-line treatment of PCOS, which are recently being examined for their extensive beneficial impacts at biochemical and molecular level of body function in Polycystic ovary syndrome. Therefore, purpose of this review is to compare the effectiveness of Metformin and Thiazolidinediones on vascular endothelial function in PCOS. MEDLINE (1966- October 2018), CINAHL (1982 to October 2018), Cochrane Central Register of Controlled Trials and Cochrane Menstrual Disorders and Subfertility Group trials register (October 2018) and Google Scholar were searched electronically without language restriction. Three Randomized controlled trials (RCTs) were selected with a total of 90 participants comparing effect of Metformin (Intervention) to Thiazolidinediones (Comparator) with an outcome on endothelial function among women with PCOS. In results, Meta-analysis shows no statistically significant difference on endothelial-dependent vasodilation between Metformin and Thiazolidinedione (p value= 0.59 at 95% CI - 1.31, 0.74).

scholarly journals Analyzing the biochemical, clinical, and hormonal characteristics of patients with polycystic ovary syndrome

2021 ◽  
Vol 38 (4) ◽  
pp. 478-484
Author(s):  
Tuğba GÜRBÜZ ◽  
Şebnem ALANYA TOSUN
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Blood Sugar ◽  
Polycystic Ovary ◽  
Fasting Blood Sugar ◽  
P Value ◽  
Type I ◽  
Ovary Syndrome ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
The Mean

To analyze the biochemical, clinical, and hormonal characteristics of patients with four phenotypes of Polycystic ovary syndrome (PCOS). A total of 225 patients admitted to Medistate Kavacık Hospital Gynecology and Obstetrics outpatient clinic and Giresun University Faculty of Medicine Gynecology and Obstetrics clinic between January 2019 and January 2020 diagnosed as PCOS and healthy controls were included in the study. The revised Rotterdam criteria were applied to diagnose PCOS. The patients with PCOS were divided into Type I classic, Type II classic, Ovulatory and Normoandrogenic PCOS. Biochemical, clinical, and hormonal values were compared. The mean age of the participants is 28 (±5.7) and the mean body mass index (BMI) is 26.15 (±5.36). The mean Ferriman Gallwey Score (FGS) is 7.4(±5.4), which is normal. There is a statistically significant difference between the four PCOS groups and control group in terms of age (p-value=0.000), BMI (p- value=0.000), Luteinizing hormone / Follicle stimulating hormone (LH/FSH) (p-value=0.000), and fasting blood sugar (p-value=0.01). There is a statistically significant difference among the four phenotypes in terms of BMI (p-value =0.002), LH/FSH (p-value =0.000), LH (p-value =0.000), free T4 (p-value =0.01), fasting insulin (p-value =0.001), total testosterone (p-value =0.000), FGS (p-value =0.000), etc. Age, BMI, LH/FSH, FSH, LH, fasting blood sugar, and hirsutism are good predictors of PCOS.

scholarly journals Dietary Modification for Reproductive Health in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yujie Shang ◽  
Huifang Zhou ◽  
Ruohan He ◽  
Wentian Lu
Keyword(s):  
Systematic Review ◽  
Reproductive Health ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Ovary Syndrome ◽  
Positive Effects ◽  
Statistical Heterogeneity

ObjectiveDiet has been reported as the first-line management of polycystic ovary syndrome (PCOS). However, the relationship between diet and fertility in PCOS is still controversial. This meta-analysis aimed to evaluate whether diet could promote reproductive health in women with PCOS while providing evidence-based nutrition advice for clinical practice.MethodsSeven databases, including Cochrane Central Register of Controlled Trials, PubMed, Embase, Web of Science, and some Chinese database, were searched up to January 31, 2021. Randomized controlled trials evaluating the effects of diet in women with PCOS were included. Based on a preregistered protocol (PROSPERO CRD42019140454), the systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Two reviewers made study selection, data extraction and bias assessment independently. Risk ratios and mean difference with 95% confidence intervals were assessed by a random-effects model. Statistical heterogeneity within comparisons was evaluated by Cochran’s Q test and quantified by the I-squared (I2) statistic.ResultsTwenty RCTs with 1113 participants were included. Results showed diet significantly related to improved fertility outcomes (increasing clinical pregnancy, ovulation and menstrual regularity rate; reducing miscarriage rate), reproductive endocrine [increasing sex hormone-binding globulin (SHBG); decreasing Anti-Müllerian Hormone (AMH), free androgen index (FAI), total testosterone (T)] and clinical hyperandrogenism (hirsutism assessed by Ferriman-Gallwey score) in PCOS. Specifically, subgroup analyses indicated low-carbohydrate diets were superior in optimizing reproductive outcomes and calorie restriction was critical in ameliorating hyperandrogenism. Additionally, the positive effects were associated with the treatment duration. The longer the duration, the greater the improvement was.ConclusionOverall, diet is an effective intervention for improving fertility health, thus professional and dynamic dietary advice should be offered to all PCOS patients, based on the changeable circumstances, personal needs and expectations of the individuals.

scholarly journals The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Meng-Fei Li ◽  
Xiao-Meng Zhou ◽  
Xue-Lian Li
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Randomized Controlled Trials ◽  
Polycystic Ovary ◽  
Chinese Herbs ◽  
Controlled Trials ◽  
Ovary Syndrome ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Reproductive Endocrine

Purpose. To evaluate the effect of berberine (BBR) on polycystic ovary syndrome (PCOS) patients with insulin resistance (IR). Methods. PubMed (in English), Medline (in English), Embase (in English), CNKI (in Chinese), WanFang DATA (in Chinese), and VIP (in Chinese) were searched for randomized controlled trials in human beings with the search terms including “polycystic ovary syndrome /PCOS” and “berberine/BBR/Huang liansu (in Chinese)/ Xiao bojian (in Chinese)” till July 2018. Relevant indices were collected and analyzed by Stata 13.0. Results. A total of 9 randomized controlled trials were included. Limited data demonstrated the results as follows: No significant difference was found between berberine (BBR) and metformin (MET) on alleviating insulin resistance, improving glycolipid metabolism, or reproductive endocrine condition. MET combined with BBR was not superior to MET alone, but cyproterone acetate (CPA) combined with BBR was superior to CPA alone in improving some of the reproductive endocrine indices. The combination of BBR and Chinese herbs also showed positive effect. However there are insufficient data to make any conclusions on the effect of BBR on PCOS-IR. Conclusion. BBR showed a promising prospect in treating PCOS-IR. But its mechanisms are still unclear, and more properly designed, randomized, double-blind, placebo-controlled trials are needed to further confirm its effect and safety.

scholarly journals Association of Metformin Pharmacogenetic with a Single Amino Acid Alteration in Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Genein Patients with Polycystic Ovary Syndrome

2019 ◽  
Author(s):  
Fatemeh Jafari ◽  
Seyed Mohsen Miresmaeili ◽  
Seyed Mehdi Kalantar
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Plasma Levels ◽  
Polycystic Ovary ◽  
Single Amino Acid ◽  
P Value ◽  
Peroxisome Proliferator ◽  
Ovary Syndrome ◽  
Peroxisome Proliferator Activated Receptor ◽  
Significant Difference ◽  
Before And After

Introduction: Polycystic ovarian syndrome (PCOS) is known as a metabolic, reproductive and ovarian degeneration disorder. Pro12 Ala mutation in peroxisome proliferator-activated receptor gamma (PPARγ) gene as a transcription factor is linked to disorder of glucose and infertility. In the patients with type 2 diabetes and polycystic ovary syndrome, metformin is the recommended first-line treatment. The aim of this study was evaluation of pharmacokinetics of metformin and the patients genotype for Pro12 Ala polymorphism. Methods: In this study, 100 women with PCOS and 100 healthy women were evaluated. Plasma levels of the FSH and LH were evaluated before and after metformin consumption in the patients.The Pro12 Ala polymorphism was detected by PCR-RFLP analysis. Results: Two patients carried GG homozygous recessive. There was no significant difference in genotypes between the healthy and patient women. There was a significant difference in plasma levels of LH, FSH and testosterone before and after treatment with metformin but there was no relationship between genotype and response to metformin (p-value = 0.59). Conclusion: Considering to this research, there is no relationship between Pro12 Ala polymorphism and metformin response in the patients, but the response to metformin for the regulation and improvement ovulation hormones in many patients is satisfactory.

scholarly journals The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Xiaorui Lyu ◽  
Taibiao Lyu ◽  
Xue Wang ◽  
Huijuan Zhu ◽  
Hui Pan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Weight Loss ◽  
Waist Circumference ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Ovary Syndrome ◽  
Receptor Agonists

Objectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systematic review and meta-analysis were conducted in our present study to evaluate the antiobesity effects of GLP-1RAs either as monotherapy or combined with MET in comparison with MET alone in overweight/obese PCOS patients. Methods. All randomized controlled trials (RCTs) which reported the efficacy of GLP-1RAs and MET in overweight/obese PCOS patients in Medline (from Pubmed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were independently searched by two reviewers. The random-effect model was used to pool data extracted from the included literature. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD42020173199). Results. A total of eight eligible RCTs were finally enrolled in our meta-analysis from the 587 retrieved literature. The results showed that GLP-1RAs alone or combined with MET was associated with a greater weight loss (N = 318, WMD = −2.61, 95% CI: −3.51 to −1.72, P ≤ 0.001 , I2 = 77.5%), more obvious reduction of waist circumference (N = 276, WMD = −3.46, 95% CI: −4.36 to −2.56, P ≤ 0.001 , I2 = 0.0%), and body mass index (BMI) (N = 318, WMD = −0.93, 95% CI: −1.60 to −0.26, P = 0.007 , I2 = 84.9%) in overweight/obese PCOS patients when compared with MET alone. Further sensitivity analysis demonstrated that the meta-analysis results of the efficacy differences in terms of body weight, waist circumference, and BMI were relatively stable and reliable. Conclusion. Our meta-analysis demonstrated that the antiobesity effect of GLP-1RAs alone or combined with MET  was superior to MET  alone in terms of weight loss, the reduction of waist circumference, and BMI. More large-scale, high-quality RCTs are needed to further confirm these results in PCOS patients.

scholarly journals Impact of rs2414096 polymorphism of CYP19 gene on susceptibility of polycystic ovary syndrome and hyperandrogenism in Kashmiri women

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sairish Ashraf ◽  
Shayaq Ul Abeer Rasool ◽  
Mudasar Nabi ◽  
Mohd Ashraf Ganie ◽  
Shariq R. Masoodi ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clinical Manifestations ◽  
Additive Model ◽  
Genotypic Frequency ◽  
Ovary Syndrome ◽  
Significant Difference ◽  
Cyp19 Gene ◽  
Reproductive Endocrine ◽  
The Impact

AbstractPolycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder in pre-menopausal women having complex pathophysiology. Several candidate genes have been shown to have association with PCOS. CYP19 gene encodes a key steroidogenic enzyme involved in conversion of androgens into estrogens. Previous studies have reported contradictory results with regard to association of SNP rs2414096 in CYP19 gene with PCOS and hyperandrogenism in different ethnic populations. Present study was aimed to investigate the impact of SNP rs2414096 polymorphism of CYP19 gene on susceptibility of PCOS and hyperandrogenism in Kashmiri women. Further we also studied the genotypic-phenotypic association for various clinical and biochemical parameters of this polymorphism. Case control study. 394 PCOS cases diagnosed on the basis of Rotterdam criteria and age matched 306 healthy women. We found a significant differences in genotypic frequency (χ2 = 18.91, p < 0.05) as well as allele frequency (OR 0.63, CI 0.51–0.78, χ2 = 17.66, p < 0.05) between PCOS women and controls. The genotype–phenotype correlation analysis showed a significant difference in FG score (p = 0.047) and alopecia (p = 0.045) between the three genotypes. Also, the androgen excess markers like DHEAS (p < 0.001), Androstenedione (p < 0.001), Testosterone (p < 0.001) and FAI (p = 0.005) were significantly elevated in GG genotype and showed a significant difference in additive model in PCOS women. rs2414096 polymorphism of CYP19 gene is associated with the risk of PCOS as well as with clinical and biochemical markers of hyperandrogenism, hence suggesting its role in clinical manifestations of PCOS in Kashmiri women.

Endothelial function in patients with polycystic ovary syndrome: a long-term follow-up study

2010 ◽  
Vol 94 (7) ◽  
pp. 2654-2658 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Lars Lind ◽  
Inger Sundström Poromaa
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Endothelial Function ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Follow Up Study ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document